Compare Carparts.Com Inc (PRTS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carparts.Com Inc vs BIO-TECHNE Corp — how do they compare? Carparts.Com Inc trades at $4.43 (market cap $39.44M), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 283× Carparts.Com Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| PRTS | TECH | |
|---|---|---|
Market Cap | $39.44M | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.40 | $72.12 |
52-Week Low | $3.88 | $43.31 |
Enterprise Value | $54.41M | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRTS trades at $4.85, down 8.49% today, reflecting a bearish technical trend. The company reported a net loss of $50.44M in 2025 despite revenue of $547.53M, with negative cash flow from operations. Recent developments include a reverse stock split and a new $25M credit facility, while analysts maintain a 60% buy rating. The stock shows oversold conditions with RSI levels below 30, indicating potential for a near-term bounce.
The outlook remains challenging due to persistent losses and negative cash flow, though cost-cutting measures and recent earnings beats offer some optimism. Key risks include execution on profitability and competitive pressures. The stock presents a high-risk opportunity for investors betting on a turnaround, supported by analyst bullishness but tempered by fundamental weaknesses.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
